Astellas Pharma (Germany) Today
| YPH Stock | EUR 9.50 0.20 2.15% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Astellas Pharma is trading at 9.50 as of the 23rd of November 2024. This is a 2.15 percent increase since the beginning of the trading day. The stock's lowest day price was 9.5. Astellas Pharma has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Astellas Pharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of February 2024 and ending today, the 23rd of November 2024. Click here to learn more.
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan. ASTELLAS PHARMA operates under Drug ManufacturersGeneral classification in Germany and is traded on Frankfurt Stock Exchange. The company has 1.83 B outstanding shares. More on Astellas Pharma
Moving together with Astellas Stock
Moving against Astellas Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Astellas Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Astellas Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Astellas Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Drug Manufacturers—General, Healthcare (View all Sectors) |
Astellas Pharma (YPH) is traded on Frankfurt Exchange in Germany and employs 14,522 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 23.71 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Astellas Pharma's market, we take the total number of its shares issued and multiply it by Astellas Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Astellas Pharma classifies itself under Healthcare sector and is part of Drug Manufacturers—General industry. The entity has 1.83 B outstanding shares.
Astellas Pharma has accumulated about 305.99 B in cash with 257.44 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 165.15, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Astellas Pharma Probability Of Bankruptcy
Ownership AllocationAstellas Pharma holds a total of 1.83 Billion outstanding shares. Over half of Astellas Pharma's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Astellas Pharma. Please watch out for any change in the institutional holdings of Astellas Pharma as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Astellas Ownership Details
Astellas Pharma Risk Profiles
Although Astellas Pharma's alpha and beta are two of the key measurements used to evaluate Astellas Pharma's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.63 | |||
| Standard Deviation | 2.19 | |||
| Variance | 4.78 | |||
| Risk Adjusted Performance | (0.06) |
Astellas Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Astellas Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Suggestion Now
Portfolio SuggestionGet suggestions outside of your existing asset allocation including your own model portfolios |
| All Next | Launch Module |
Astellas Pharma Corporate Management
Elected by the shareholders, the Astellas Pharma's board of directors comprises two types of representatives: Astellas Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Astellas. The board's role is to monitor Astellas Pharma's management team and ensure that shareholders' interests are well served. Astellas Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Astellas Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Minoru Kikuoka | CFO Officer | Profile | |
| Naoki BSc | Chief VP | Profile | |
| Kenji Yasukawa | CEO Pres | Profile | |
| Stig Ogata | VP Communications | Profile | |
| Katsuyoshi Sugita | Chief Officer | Profile | |
| Chihiro Yokota | Devel Devel | Profile | |
| Yoshitsugu Shitaka | Chief Officer | Profile |
Other Information on Investing in Astellas Stock
Astellas Pharma financial ratios help investors to determine whether Astellas Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Astellas with respect to the benefits of owning Astellas Pharma security.